126541-88-6

Basic information

• Product Name: 3-Hydroxy-4-(trifluormethyl)benzoesaeure-methylester
• Synonyms: 3-Hydroxy-4-(trifluormethyl)benzoesaeure-methylester
• CAS NO: 126541-88-6
• Molecular Weight: 220.148
• Mol File: 126541-88-6.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 3-Hydroxy-4-(trifluormethyl)benzoesaeure-methylester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Hydroxy-4-(trifluormethyl)benzoesaeure-methylester(126541-88-6)
• EPA Substance Registry System: 3-Hydroxy-4-(trifluormethyl)benzoesaeure-methylester(126541-88-6)

Safety Data

• Hazardous Substances Data: 126541-88-6(Hazardous Substances Data)

Upstream product

• 115754-21-7 3-fluoro-4-(trifluoromethyl)benzoic acid 
• 957205-75-3 methyl 3-(benzyloxy)-4-(trifluoromethyl)benzoate 
• 116965-16-3 3-nitro-4-(trifluoromethyl)benzoic acid 
• 125483-00-3 3-amino-4-(trifluoromethyl)benzoic acid 
• 455-24-3 4-trifluoromethylbenzoic acid 
• 67-56-1 methanol 
• 126541-87-5 3-hydroxy-4-trifluoromethylbenzoic acid 
• 186581-53-3 diazomethane 

Downstream Products

• 126541-89-7 3-Hydroxy-2-nitro-4-(trifluormethyl)benzoesaeure-methylester 
• 126541-90-0 3-Hydroxy-6-nitro-4-(trifluormethyl)benzoesaeure-methylester 
• 126542-07-2 5-Hydroxy-2-nitro-4-trifluoromethyl-benzoic acid 
• 126541-93-3 3-Hydroxy-2-nitro-4-(trifluormethyl)benzoesaeure 
• 438571-15-4 3-[2-(2,4-dichloro-phenyl)-ethoxy]-4-trifluoromethyl-benzoic acid 
• 438571-14-3 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-trifluoromethyl-benzoic acid methyl ester 

Relevant articles and documents

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.

HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE

To provide a novel compound which has S1P receptor agonistic activity, exhibits excellent immunosuppressing effect, gives less adverse side effects, and can be orally administered. The invention provides a compound represented by general formula (I) (wherein A is a single bond, -O-, or - CH2-; R1 represents a hydrogen atom or a C1-C6 alkyl group, and V represents any one group selected from among the following groups (1) to (3) : (1) -G1-, (2) -G2-N(R2) -G3-, and (3) a group represented by formula 2, wherein each of Z1 and Z2 represents a hydrogen atom or a C1-C6 alkyl group, Z3 represents a hydrogen or the like, Q represents -CH2-O- or the like, and Y represents a group represented by foumula 3, a salt thereof, or a solvate thereof.

Demethyl(trifluoromethyl)actinomycins

The synthesis of new 4-(trifluoromethyl)benzoic acid derivatives 2-10 and their coupling with amino acids and peptides 12, 13, 15 is described.They serve as precursors for the synthesis of the hitherto unknown demethyl(trifluoromethyl)actinocin dimethyl esters 11, demethyl-trifluoromethyl-actinocinyl peptides 14, 16, 18 and the demethyl-trifluoromethyl-actinomycins 17.Although spacially comparable with the methyl residues, the 4- and 6-trifluoromethyl groups have unexpected strong influences on the antibiotic and cytostatic properties of the actinomycins.The CH3/CF3 exchange makes it possible to bring NMR-analytically useful hetero nuclei into the centre of the actinomycin/DNA complex (Figure 1).